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Abstract
Background & Aims: The use of complementary and alternative medicine (CAM) in 
patients with chronic hepatitis B (CHB) can interact with antiviral treatment or influ‐
ence health‐seeking behaviour. We aimed to study the use of individual CAM modali‐
ties in CHB and explore determinants of use, particularly migration‐related, 
socio‐economic and clinical factors.
Methods: A total of 436 CHB outpatients who attended the Toronto Centre for Liver 
Disease in 2015‐2016 were included in this cross‐sectional study. Using the compre‐
hensive I‐CAM questionnaire and health records, data were collected on socio‐de‐
mographic and clinical variables and on usage of 16 CAM modalities in the last year.
Results: Sixty percent of patients were male, 74% were Asian and 46% were using 
antiviral treatment. Three‐hundred and nine (71%) patients used CAM. Vitamin/min‐
eral preparations (45% of patients) were most commonly used. Overall CAM use and 
the specific use of potentially injurious CAM, such as green tea extract (9.2%) and St. 
John's wort (0.2%), were not associated with liver disease severity. Female sex, family 
history of CHB, lower serum HBV DNA, and higher socio‐economic status were in‐
dependently associated with bio‐holistic CAM use, the clinically most‐relevant CAM 
group (P < 0.05); ethnicity, antiviral therapy use and liver disease severity were not.
Conclusions: CAM use among CHB patients was extensive, especially use of vitamin 
and mineral preparations, but without direct influence on liver disease severity. Bio‐
holistic CAM use appeared to be associated with socio‐economic status rather than 
with ethnicity or liver disease severity. Despite the rare use of hepatotoxins, physi‐
cians should actively inquire about it.
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1  | INTRODUC TION
Chronic hepatitis B (CHB) affects approximately 240 million people 
worldwide and the associated liver‐related morbidity and mortality 
continue to rise.1‐3 Global migration is changing the epidemiology 
of CHB, especially in low‐endemic regions (North‐America, Europe) 
with a high immigration rate from highly endemic areas.4,5 These epi‐
demiological shifts increase the ethno‐cultural diversity, and could 
therefore influence the use of and perceptions on conventional 
Western medicine and on complementary and alternative medicine 
(CAM).
Patients with chronic diseases increasingly use CAM in addi‐
tion to, or as a replacement of conventional treatments.6 CAM is 
defined as ‘a group of diverse medical and health care systems, 
practices, and products that are not generally considered part of 
conventional medicine’.7 Examples of CAM include Traditional 
Chinese Medicine, acupuncture and dietary supplements. The 
proportion of patients with chronic liver disease who use CAM 
varies widely from 27% to 80%.8‐11 Patients use CAM both for 
disease‐related symptoms as well as for general well‐being.6 The 
identification of patterns in CAM use could be of great relevance 
to health care providers, since CAM products may interact with 
antiviral treatment or influence the health care‐seeking behaviour 
of patients.12,13 Insight into CAM use is especially important for an 
ethnically diverse population such as those with CHB, where ethnic 
and acculturation factors can enlarge differences in CAM use and 
clinical outcomes.
The prevalence and predictors of individual CAM modalities in 
patients with CHB have not been well characterized. Previous stud‐
ies on CAM use in CHB focused on specific types of CAM, were 
restricted to subgroups of patients, or evaluated few clinically im‐
portant determinants.9,14,15 We evaluated the use of various CAM 
modalities and its relation to clinical, socio‐economic and migration‐
related factors in a large, multi‐ethnic CHB cohort.
2  | PATIENTS AND METHODS
2.1 | Study population
Patients with CHB aged 18 years or above who attended the hepa‐
tology outpatient clinic of the Toronto Centre for Liver Disease, 
Canada, between January 1, 2015 and October 31, 2016 were in‐
vited to participate in this cross‐sectional study. Both new patients 
and those in follow‐up were eligible. The Toronto Centre for Liver 
Disease is the only specialized Liver Unit in the city of Toronto and 
comprises a wide variety of immigrants from around the globe. We 
excluded patients with a history of hepatocellular carcinoma, HIV 
co‐infection, liver decompensation and organ‐ or bone marrow 
transplant. The Research Ethics Board of University Health Network 
approved this study which was performed in accordance with the 
Good Clinical Practice guidelines and the Declaration of Helsinki. All 
patients provided written consent.
2.2 | Data collection
To address CAM use in patients with CHB, we developed a modi‐
fied version of the International Complementary and Alternative 
Medication Questionnaire (I‐CAM‐Q).16 The modified I‐CAM‐Q is 
a standardized comprehensive survey that comprises demographic, 
ethnic, socio‐economic and clinical data, and use of 16 CAM thera‐
pies as classified by the National Center for Complementary and 
Alternative Medicine. The I‐CAM‐Q was designed for use across dif‐
ferent populations and countries, but has not been validated. Both 
an English and Mandarin version of the modified I‐CAM‐Q was avail‐
able. Patients completed the questionnaire at the time of an outpa‐
tient visit with the help of a research coordinator and if needed a 
translator. Any omissions or ambiguities in responses were followed 
up during the day of clinic visit or with telephone calls. Ethnicity‐
related questions involved country of birth, ethnicity, primary lan‐
guage, immigrant status and time since immigration. Ethnicity was 
categorized into five groups: Chinese (China, Hong Kong, Taiwan), 
South‐East Asian (Philippines, Korea, Vietnam, Thailand, Cambodia, 
Laos, Indonesia, Malaysia), South‐Asian (India, Pakistan, Afghanistan, 
Bangladesh, Tibet), Caucasian (Europe, Russia, Turkey, Middle‐East, 
North‐Africa, Hispanic/Latino) and Black (Africa, Haiti, Jamaica). 
Socio‐economic information included annual household income 
over the last 12 months, highest level of education, employment 
status and private insurance coverage. Clinical data (body height 
and weight, duration of hepatitis B virus (HBV) infection, serum ALT, 
serum HBV DNA, HBeAg status, cirrhosis (defined as Metavir F4/
Ishak stage 6 on liver biopsy, or radiographic evidence of cirrhosis), 
current and past CHB treatment, duration of CHB treatment, as well 
as family history of CHB and/or hepatocellular carcinoma were re‐
trieved from patient medical records and the questionnaire.
CAM therapies have been categorized by the National Center for 
Complementary and Alternative Medicine of the National Institutes 
of Health.7 We obtained information on the following CAM domains 
and modalities from the survey: holistic therapies (homeopathy, 
acupuncture, naturopathy), biologically‐based practices (herbal 
products, vitamin and mineral preparations, dietary supplements), 
manipulative and body‐based therapies (chiropractic, massage, ma‐
nipulation), mind–body medicine (meditation, spiritual therapy, visu‐
alization/guided imagery, health prayers, attendance of a traditional 
healing ceremony, qi gong, tai chi, yoga). For every type of CAM, 
Key Points
• The use of complementary and alternative medicine was 
common in this clinic‐based population of patients with 
chronic hepatitis B.
• Vitamin and mineral preparations were used most fre‐
quently, whereas compounds that might damage the 
liver were rarely consumed.
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patients reported visits to CAM providers, the use of CAM products, 
the frequency and duration of use, the primary aim (treatment of 
acute or chronic symptoms of CHB, general well‐being, other rea‐
son), the efficacy of CAM practice, (reasons for) non‐disclosure and 
physician inquiry about of CAM use.
2.3 | Statistical analysis
Baseline characteristics are reported in means ± standard deviations 
(SD) for continuous variables, or frequency (percentage) for categor‐
ical variables. Differences in baseline characteristics and outcomes 
were analysed using chi‐squared test, Fisher's exact test, Student's 
t test or Mann‐Whitney test, where appropriate. Current CAM use 
was defined as annual or more frequent use of at least one of the 
CAM modalities. To evaluate whether ethnicity, antiviral treatment 
and hepatitis activity were associated with use of CAM, predictors 
that were univariably associated with CAM use in logistic regression 
(p‐value < 0.10) were analysed in multivariable logistic regression. 
For this analysis, the clinically most relevant CAM groups (holistic 
and biologically‐based therapies) were included. These bio‐holistic 
CAM therapies were selected for further analysis because of po‐
tentially relevant clinical interactions. In addition there was insuf‐
ficient statistical power to include other CAM modalities. Covariates 
included age, sex, ethnicity, duration of CHB, current antiviral treat‐
ment, previous use of pegylated (PEG‐) interferon, previous use of 
nucleos(t)ide analogues (NA), cirrhosis, serum ALT level, serum HBV 
DNA level, HBeAg status, body mass index (BMI), family history of 
CHB and/or liver cancer, time since immigration, immigrant status, 
highest level of education, employment status, annual income and 
private drug plan coverage. All p‐values were two‐sided with a sig‐
nificance level of 0.05. Analyses were performed in SPSS (v. 22.0, 
Chicago, IL).
3  | RESULTS
3.1 | Patient characteristics
A total of 600 patients were approached in the inclusion period, 
of whom 436 (73%) patients completed the survey. Patients were 
excluded due to the following: HBsAg negative (n = 7), relevant 
co‐morbidity (n = 7), acute HBV (n = 2), or refusal to participate 
(n = 148). Sociodemographic and clinical characteristics of enrolled 
patients according to CAM use are shown in Table 1. The mean (SD) 
age was 49 (14) years, 263 (60%) patients were male, and 201 (46%) 
currently used antiviral treatment for CHB. Two hundred eight (48%) 
patients were Chinese, 86 (20%) South‐East Asian, 28 (6.4%) South‐
Asian, 72 (17%) Caucasian, 39 (8.9%) Black and 3 (0.7%) patients had 
more than one race/ethnicity. Two‐hundred and nine (48%) patients 
born abroad had lived for 20 or more years in Canada. Two‐hundred 
and sixty‐four (61%) patients had finished college or higher educa‐
tion and 235 (54%) did not have any private insurance plan. Fifteen 
percent was HBeAg positive, the mean ALT was 1.5 (0.3) log IU/mL, 
median HBV DNA 1.8 (0.0‐3.6) log IU/mL, and 65 (15%) patients 
were cirrhotic. Two‐hundred and three (47%) patients had a family 
history of CHB.
Several characteristics were significantly different between 
CAM users and CAM non‐users. Notably, CAM users were pre‐
dominantly female, South‐Asian or Black, had a higher socio‐
economic status, and more often a family history of CHB. Other 
baseline characteristics were comparable between CAM users and 
CAM non‐users.
3.2 | Patterns of CAM use
Three hundred nine (71%) patients had used CAM at least once dur‐
ing the past 12 months, and two hundred fifty‐six (59%) patients had 
used CAM regularly (at least monthly; Figure 1). Biologically based 
(51%) and mind–body therapies (35%) were the most frequently 
utilized CAM domains. Within these domains, vitamin and mineral 
preparations (45%), spiritual practices (29%), and dietary supple‐
ments (21%) were the most common CAM modalities. The use of 
body‐based therapies (24%) was moderate and the use of holistic 
practices (8.9%) was low.
CAM use was significantly different among different ethnicities 
(64% in Chinese, 72% in Caucasians, 76% in SE‐Asians, 79% in South‐
Asian, and 87% in Blacks; P = 0.03 (Table 1 and Table S1). Specifically, 
mind‐body medicine was practised more often by South‐Asian (54%) 
and Black patients (77%) than other ethnic groups (22%; P < 0.005). 
Homeopathy (2.8%) and naturopathy (1.4%) were more often used 
by Caucasian than other groups (P = 0.03). The overall use of vita‐
min and mineral preparations (45%) and herbal product use (16%) 
did not differ significantly among ethnic groups. Vitamin and mineral 
supplements predominantly comprised of vitamin D (39%), multivi‐
tamins (38%), calcium (26%), vitamin C (19%), and omega‐3 fatty acid 
(19%). Ginger extract (34%), milk thistle (15%) and ginseng (5.9%) 
were the most commonly used herbal preparations.
The use of CAM products with a reported hepatoprotective or 
hepatitis B infection‐altering effect (milk thistle and ginger extract) 
was very low (3%) and was not related to subjects’ liver disease 
severity, as was reflected by no association with serum ALT, HBV 
DNA or presence of cirrhosis (P > 0.05). The use of green tea extract 
(9.2%) and St. John's wort (0.2%), the only known potentially harmful 
CAM products in this study, was not associated with liver disease 
severity (P > 0.05).
3.3 | Attitudes towards CAM use
The main reason to use herbal products was to improve general 
well‐being (63%; Table 2). Thirty‐two percent of patients used herbal 
products for liver‐related symptoms, compared to 2.6% of vitamin 
and mineral product users (P < 0.005). Homeopathy and spiritual 
therapies were rated predominantly as very helpful, whereas most 
other CAM therapies were considered helpful. A quarter of patients 
rated vitamin/mineral (24%) and other supplements (25%) as not 
helpful at all. The majority of patients (87%) started CAM therapy 
before they were diagnosed with CHB and had been using it for at 
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TA B L E  1   Patient characteristics according to CAM use in the last year
 Overall CAM (n = 309) No CAM (n = 127)
Bio‐holistic 
CAMa  (n = 235)
Demographics
Age, y 49 (14) 48 (14) 51 (14)
Sex, male 177 (57) 86 (68) 125 (53)
Race/ethnicity
Chinese 134 (43) 74 (58) 113 (48)
South‐East Asian 65 (21) 21 (17) 48 (20)
South‐Asian 22 (7.1) 6 (4.7) 11 (4.7)
Caucasian 52 (17) 20 (16) 44 (19)
Black 34 (11) 5 (3.9) 17 (7.2)
Mixed 2 (0.6) 1 (0.8) 2 (0.9)
Socio‐economic factors
Married 210 (68) 91 (72) 160 (68)
Duration of stay in Canada
0‐3 y 28 (9.1) 3 (2.4) 12 (5.1)
4‐19 y 107 (35) 60 (48) 80 (34)
≥20 y 174 (56) 63 (50) 143 (61)
Residency status
Citizen 252 (82) 20 (16) 201 (86)
Primary language
English 187 (61) 58 (46) 137 (59)
Mandarin/Cantonese 85 (28) 51 (40) 75 (33)
Other 33 (11) 18 (14) 19 (8.2)
Education level
≤ High school 110 (36) 62 (49) 80 (34)
College/Bachelor 161 (52) 53 (42) 122 (52)
Master/Doctorate 38 (12) 12 (9.4) 33 (14)
Employment status
Employed 222 (72) 94 (75) 164 (70)
Unemployed 32 (10) 17 (14) 21 (8.9)
Retired 55 (18) 15 (12) 50 (21)
Annual income, Canadian dollar
<$25.000 69 (28) 42 (40) 49 (21)
$25.000‐$49.999 63 (25) 32 (31) 46 (20)
$50.000‐$99.999 77 (31) 18 (17) 60 (26)
≥$100.000 41 (16) 13 (12) 35 (15)
Private drug plan
None 146 (54) 89 (73) 111 (52)
50%‐79% 34 (13) 7 (5.8) 29 (14)
80%‐99% 49 (17) 13 (11) 38 (18)
≥100% 43 (16) 12 (10) 33 (15)
Clinical data
Duration of HBV infection, y 17 (12) 16 (10) 18 (12)
Current CHB therapy 140 (45) 61 (48) 114 (49)
Duration, y 5.3 (9.4) 4.6 (3.1) 5.5 (10.4)
(Continues)
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least 5 years, especially acupuncture (71%), visualization (57%) and 
herbal medicine (67%).
Forty‐three percent of physicians had actively inquired about 
CAM use (Supplementary Table 1). Doctors had inquired about CAM 
use less often in Caucasian patients (33%) than in Chinese patients 
(46%; P = 0.06). Fifty‐two percent of patients had not informed their 
physicians about CAM use, ranging from 46% (Black patients) to 
64% (South‐Asian patients), and this did not differ between ethnic 
groups. The main reasons for patients not to disclose CAM use were: 
not considered important to inform treating physician, non‐liver 
related CAM use, not inquired by physician, anticipated physician 
disinterest or disapproval, and already informed general practitioner 
or other treating physician.
3.4 | Determinants of bio‐holistic CAM use
Determinants for the use of the clinically most relevant CAM group, 
(bio‐holistic CAM, were studied with logistic regression (Table 3). 
The bio‐holistic CAM therapies were selected because of possible 
clinical interactions and limited statistical power to study other 
 Overall CAM (n = 309) No CAM (n = 127)
Bio‐holistic 
CAMa  (n = 235)
Previous CHB therapy 135 (44) 53 (42) 107 (46)
Nucleos(t)ide analogue 128 (42) 51 (40) 100 (43)
 (PEG‐)interferon 24 (7.8) 10 (7.9) 19 (8.1)
Family history of CHB 156 (51) 47 (37) 126 (54)
Family history of liver cancer 52 (17) 20 (16) 45 (19)
Laboratory
ALT, log IU/L 1.5 (0.3) 1.5 (0.2) 1.5 (0.3)
HBV DNA, log IU/mLb  1.9 (0.0‐3.5) 1.6 (0.0‐3.6) 1.6 (0.0‐3.0)
HBeAg positive 43 (14) 21 (17) 26 (11)
BMI, kg/m2 25 (4.2) 25 (4.2) 25 (4.1)
Cirrhosis 50 (16) 15 (12) 39 (17)
Data represented as n (%) or mean (standard deviation).
ALT, alanine aminotransferase; CAM, complementary and alternative medicine; CHB, chronic hepatitis B; HBV, hepatitis B virus; PEG, pegylated.
aUse of biologically based and holistic therapies combined. 
bMedian (interquartile range). 
TA B L E  1   (Continued)
F I G U R E  1   Use of CAM modalities in 
the last 12 mo in 436 patients with CHB
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TA B L E  3   Logistic regression on bio‐holistic CAM usea 
 
Univariable Multivariable
OR 95%CI P OR 95%CI P
Demographics
Age, y 1.03 1.02‐1.05 <0.005*    ns
Sex, female vs male 2.13 1.44‐3.14 <0.005*  2.18 1.35‐3.59 <0.005* 
Race/ethnicity
Chinese 1.00  0.10   ns
South‐East Asian 1.64 0.99‐2.73     
South‐Asian 0.63 0.26‐1.49     
Caucasian 1.57 0.91‐2.69     
Black 0.98 0.49‐1.98     
Socio‐economic factors
Married 0.86 0.57‐1.30 0.48    
Duration of stay in Canada
0‐3 y 1.00  <0.005*    ns
4‐19 y 1.23 0.53‐2.86     
≥20 y 2.55 1.13‐5.77     
Residency status
Citizen vs non‐citizen 1.95 1.15‐3.32 0.01*    ns
Primary language
English 1.00  0.17    
Mandarin/Cantonese 0.75 0.49‐1.14     
Other 0.53 0.28‐1.02     
Education level
≤ High school 1.00  <0.005*  1.00  <0.005* 
College/Bachelor 1.89 1.24‐2.86  2.03 1.23‐3.34 0.01* 
Master/Doctorate 2.64 1.39‐5.02  2.95 1.40‐6.20 <0.005* 
Employment status
Employed 1.00  <0.005*  1.00  <0.005* 
Unemployed 0.88 0.47‐1.65  1.45 0.72‐2.96 0.30
Retired 4.14 2.35‐7.29  5.22 2.72‐10.03 <0.005* 
Annual income, Canadian dollar
<$25.000 1.00  0.02*    ns
$25.000‐$49.999 1.00 0.57‐1.78     
$50.000‐$99.999 2.09 1.19‐3.65     
≥$100.000 1.7 0.94‐3.45     
Private drug plan
None 1.00  <0.005*  1.00  0.02* 
50%‐79% 2.86 1.45‐5.66  2.81 1.31‐6.07 0.01* 
80%‐99% 2.08 1.18‐3.67  2.07 1.09‐3.94 0.03* 
≥100% 1.64 0.91‐2.97  1.63 0.83‐3.19 0.16
Clinical data
Duration of HBV infection
0‐9 y 1.00  0.12    
10‐19 y 1.41 0.89‐2.21     
20‐29 yr 1.53 0.90‐2.61     
(Continues)
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CAM products. Female sex (OR for female versus male: 2.18; 95%CI: 
1.35‐3.59; P < 0.005), higher education level (Master's degree vs ≤ 
High school, OR: 2.95; 1.40‐6.20; P < 0.005), employment status 
(OR for retired vs employed: 5.22; 2.72‐10.03; P < 0.005), higher pri‐
vate drug plan coverage (80%‐100% vs. none, OR: 2.07; 1,98‐3,94; 
P = 0.02), lower HBV DNA (OR: 0.89; 0.81‐0.98; P = 0.02) and a 
family history of CHB (OR: 1.65; 95%CI: 1.07‐2.55; P = 0.03) were 
independently associated with use of bio‐holistic CAM modalities. 
Age, ethnicity, immigrant status, time since immigration, and primary 
language were not associated.
4  | DISCUSSION
In this clinic‐based study, we reported the prevalence of CAM use 
and individual CAM modalities in a large multi‐ethnic CHB cohort, 
and examined factors that determined CAM usage. A majority of 
patients used CAM in the past year (71%), ranging from 64% for 
Chinese to 78% in non‐Asian patients. Vitamin and mineral prepa‐
rations were used most frequently, followed by spiritual healing 
practices, body‐based therapies and herbal medicine. Variables 
significantly associated with bio‐holistic CAM use were female sex, 
higher socio‐economic status, lower serum HBV DNA, and a fam‐
ily history of CHB; ethnicity and migration‐related factors were not.
The use of CAM in our study was extensive compared to previ‐
ous studies in CHB, but was not associated with the use of antiviral 
treatment or disease severity. Two previous studies in CHB reported 
that 46% of children used CAM, and 32% of patients in Hong Kong 
ever used Traditional Chinese Medicine, compared to 19% among 
Chinese patients in our study.14,15 Other epidemiological studies in 
non‐CHB chronic liver disease showed substantial variation in CAM 
use rates (27%‐80%).8,9,11,17 The comparatively high rate of CAM use 
in this study could be due to the comprehensive definition of CAM, 
the population under study, and the setting where patients were in‐
vestigated (tertiary referral centre versus family practice).18,19
Prolonged and/or frequent use of presumed noxious CAM com‐
pounds can adversely impact clinical disease markers in liver disease, 
due to herb‐drug interactions or influence of cytochrome P450 sys‐
tems. These findings mainly stem from studies in liver diseases other 
than CHB.20‐22 In our study, patients were taking mainly ‘western 
style’ CAM products (mostly vitamins) and hardly any herbals or sup‐
plements with possible beneficial effects for HBV or liver disease. 
The use of potentially harmful CAM products such as green tea ex‐
tract or St. John's wort was very low and not associated with liver 
disease severity, although this should be interpreted cautiously as 
few participants used these CAM products and no follow‐up data 
was available. We are concerned when patients take a mix of herbs 
that are difficult to identify, but this did not occur frequently in our 
population, which was probably biased because all patients visited 
western style practitioners in a hospital. Alternatively, it might be 
possible that patients used CAM products which contained hepato‐
toxins but that they did not consider these as CAM. Nonetheless, this 
was the largest multi‐ethnic clinic‐based study in CHB and therefore 
probably indicative of real world CAM use in CHB in North‐America. 
In order to monitor the (safe) use of CAM, physicians should be en‐
couraged to actively ask about CAM use and specific harmful prod‐
ucts, which was currently only done by less than half of the treating 
physicians.
 
Univariable Multivariable
OR 95%CI P OR 95%CI P
≥30 yr 2.18 1.07‐4.45     
Current CHB therapy 1.13 0.77‐1.65 0.53    
Previous CHB therapy 1.25 0.85‐1.83 0.26    
 (PEG‐)interferon 1.78 0.88‐3.61 0.11    
Nucleos(t)ide analogue 1.12 0.76‐1.64 0.57    
Family history of CHB 1.93 1.32‐2.84 <0.005*  1.65 1.07‐2.55 0.03* 
Family history of liver 
cancer
1.53 0.92‐2.53 0.10   ns
Laboratory
ALT, log IU/L 0.47 0.22‐1.03 0.06   ns
HBV DNA, log IU/mL 0.89 0.82‐0.97 0.01*  0.89 0.81‐0.98 0.02* 
HBeAg positive 0.48 0.27‐0.85 0.01*    ns
BMI, kg/m2 0.99 0.94‐1.03 0.58    
Cirrhosis*  1.09 0.64‐1.86 0.74    
ALT, alanine aminotransferase; CAM, complementary and alternative medicine; CHB, chronic hepatitis B; HBV, hepatitis B virus; ns, not significant; 
PEG, pegylated.
aUse of biologically based and holistic therapies combined, at least monthly. 
*P < 0.05. 
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This study was the first to investigate the influence of ethnic‐
ity on CAM modalities in North America, which contains a pre‐
dominantly immigrant population with CHB. The demographics of 
Toronto, one of the most multicultural and multiracial cities world‐
wide where 52% of the population is composed of visible minorities, 
enabled us to comprehensively evaluate the role of ethnicity in CAM 
use.23 CAM use in general differed by ethnicity, specifically for spiri‐
tual therapy, yoga, tai chi and homeopathy. The use of spiritual ther‐
apy was higher in South‐Asian and Black patients compared to other 
patients. Vitamin and mineral preparation use was surprisingly sim‐
ilar between ethnic groups, possibly because these products have 
become popular among the population at large in Western countries. 
Earlier studies on CAM use in ethnic subgroups in Canada combined 
healthy subjects and patients with chronic conditions, thereby mix‐
ing different motives and patterns of use.17,24 Remarkably, ethnicity 
and migration‐related factors were not associated with oral CAM 
use after adjustment in multivariable analysis. Other determinants, 
such as higher socio‐economic status, were either much stronger 
predictors of CAM use or correlated with migration‐related factors, 
so that any effect of ethnicity and migration‐related factors might 
be unobservable, as seen in prior research.18 The high cost of CAM 
products likely restricted access to the more affluent patients, re‐
gardless of ethnic background. These findings suggest that health 
care providers of CHB should focus on socio‐economic status rather 
than ethnic or cultural factors when inquiring about CAM use.
The use of CAM is widespread and growing in populations where 
evidence‐based medicine is dominant.25,26 US adults spent $33.9 
billion out‐of‐pocket annually on CAM visits and products, whereas 
one in every two European citizens uses CAM, which underlines the 
breadth of CAM use nowadays.25,26 Apart from reporting CAM use 
rates in chronic liver disease patients, it is equally important to gain 
insight in why patients opt for non‐conventional medical therapies. 
This study showed that most patients used CAM for reasons unre‐
lated to their chronic liver disease, except for herbal medicine. A 
possible explanation is that the most commonly used herbal prod‐
ucts milk thistle (Silybum marianum) and several Traditional Chinese 
Medicine products have been associated with hepatoprotective 
effects, while the efficacy of other CAM therapies is less clear.12,27‐
30 Additionally, the non‐liver related use of CAM could reflect an 
increasing demand for ‘salutogenesis’, an approach that focuses on 
determinants of well‐being, rather than on determinants of disease, 
and is key to the CAM paradigm.31
Strong aspects of this study are the inclusion of a large, multi‐
ethnic cohort of CHB patients who completed an extensive survey 
on CAM‐related factors. Conversely, the inherent recall bias for 
questionnaires and cross‐sectional design restricted us to study 
long‐term consequences of CAM use. Future studies on CAM use in 
CHB could focus on these long‐term effects and associated factors.
In summary, CAM use in this clinic‐based population of CHB pa‐
tients was common and the CAM products that patients used, pri‐
marily vitamin and mineral preparations, appeared to be safe. Few 
patients had used CAM products that were considered to be harm‐
ful. CAM use was associated with female sex, higher socio‐economic 
status, lower HBV DNA and a family history of CHB; not with ethnic 
background, antiviral treatment or liver disease severity. Most treat‐
ing physicians had not inquired about the use of CAM, neither had 
most of the patients discussed its use.
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